GLP-1 receptor agonist
Lixisenatide dose
Answer
FDA label for Soliqua 100/33: The recommended starting dosage is 15 units subcutaneously once daily. Half-life on the label: approximately 3 hours. Trials with posted results tested 1 dose, most often 20 mcg.
Not dosing advice.
FDA LABEL
What the approved labels state
Soliqua 100/33 BLA208673 · label of 2026-03-18 Regulator
The recommended starting dosage is 15 units subcutaneously once daily.
Maximum daily dosage is 60 units (60 units of insulin glargine and 20 mcg of lixisenatide).
Half-life: approximately 3 hours (section 12.3).
IN TRIALS
Doses tested in 27 trials with posted results
| Dose in the arm title | Trials | People on it | Phases |
|---|---|---|---|
| 20 mcg | 1 | 48 | 2 |
Trial register Read from the titles of arms that received Lixisenatide (n ≥ 20). An arm naming several doses counts under each; a schedule or escalation is on the trial record. All trials.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.